NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer
December 06 2017 - 6:50AM
Business Wire
Expands leadership team with seasoned
commercial executive
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® for lid and lash hygiene in the domestic eye care market,
announces the appointment of Lewis J. Stuart as Chief Commercial
Officer. Mr. Stuart joined NovaBay on December 1 and brings more
than 30 years of biopharmaceutical industry experience. At NovaBay,
he will be responsible for leading all commercial activities,
including driving sales and revenue growth of Avenova in new and
existing markets, and expanding the Company’s global commercial
channel.
“Lewis is a results-driven executive with extensive experience
in successfully launching and growing major medical products,
making him an ideal fit for this position,” said Mark Sieczkarek,
NovaBay’s President and CEO. “He joins us with a track record of
launching first-in-class products, a focus on maximizing
productivity and strategic insights. We look for Lewis to make
impactful contributions to our commercial organization as we focus
on accelerating sales growth of Avenova, and welcome him to our
Company.”
“Avenova offers multiple important benefits to a large and
relatively untapped segment of the ophthalmology market,” commented
Mr. Stuart. “I am delighted to join the NovaBay team and look
forward to leading the commercial operations and driving Avenova’s
ongoing success.”
Prior to NovaBay, Mr. Stuart was Vice President, U.S. Oncology
for Genomic Health, where he led the marketing, sales, and medical
affairs teams for their oncology franchise. He was also a member of
the Board of Directors for Linkage Biosciences, Inc. recently
acquired by Thermo Fisher, Inc.
Previously, he served as President and General Manager of
Genetic Technologies, a women’s health/oncology company, where he
established a U.S.-based molecular diagnostics division. He has
also held leadership positions as Senior Vice President, Commercial
Operations at CV Therapeutics, a Gilead Sciences acquisition, and
Vice President, Sales & Community Marketing at Agouron
Pharmaceuticals, before its acquisition by Pfizer, Inc.
Mr. Stuart holds a BA in Communications & Marketing
Management from Virginia Polytechnic and State University.
About Avenova®Avenova is NovaBay Pharmaceuticals’
main commercial focus. Data from a multicenter clinical study show
that Avenova reduced bacterial load, the underlying cause of
blepharitis, on ocular skin surface by more than 90%. Laboratory
tests show that hypochlorous acid has potent antimicrobial activity
in solution yet is non-toxic to mammalian cells and also
neutralizes bacterial toxins. Avenova is marketed to optometrists
and ophthalmologists throughout the U.S. by NovaBay’s direct
salesforce. It is accessible from more than 90% of retail
pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmerisourceBergen.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®NovaBay Pharmaceuticals, Inc. is a
biopharmaceutical company focusing on commercializing and
developing its non-antibiotic anti-infective products to address
the unmet therapeutic needs of the global, topical anti-infective
market with its two distinct product categories: the NEUTROX®
family of products and the AGANOCIDE® compounds. The Neutrox family
of products includes AVENOVA® for the eye care market, NEUTROPHASE®
for wound care market, and CELLERX® for the aesthetic dermatology
market. The Aganocide compounds, still under development, have
target applications in the dermatology and urology markets.
Forward-Looking StatementsThis release contains
forward-looking statements that are based upon management's current
expectations, assumptions, estimates, projections and
beliefs. These statements include, but are not limited to,
statements regarding any potential benefit or deleterious effect
due to the transition in management, inclusive of any possible
effect that would have generally on the Company’s expected future
financial results. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results or achievements to be materially different and adverse from
those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to difficulties or delays in manufacturing,
distributing, and selling the Company's products, unexpected
adverse side effects or inadequate therapeutic efficacy of our
product, the uncertainty of patent protection for the Company's
intellectual property, and any potential regulatory
problems. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay's latest Form 10-K and Form 10-Q
filings with the Securities and Exchange Commission, especially
under the heading "Risk Factors." The forward-looking
statements in this release speak only as of this date, and NovaBay
disclaims any intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress:Like us
on FacebookFollow us on TwitterConnect with
NovaBay on LinkedInJoin us
on Google+Visit NovaBay’s Website
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171206005212/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information:Please call us toll free:
1-800-890-0329 or
email sales@avenova.comwww.Avenova.comorFrom the CompanyJack McGovern,
510-899-8800Chief Financial
Officerjmcgovern@novabay.comorInvestor
ContactLHA Investor RelationsJody Cain,
310-691-7100Jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024